Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Q1 2019 Financial Results and Business Update

Lausanne, Switzerland, May 15, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in...
April 01, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

Lausanne, Switzerland, April 1, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
April 01, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

LAUSANNE, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
March 29, 2019 02:00 ET | Source: AC Immune SA

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference

Demonstrated high-affinity binding to human Parkinson's disease-brain derived alpha-synuclein Potentially first diagnostic for detecting and monitoring Parkinson's disease Further reinforces...
March 29, 2019 02:00 ET | Source: AC Immune SA

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference

Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther reinforces...
March 27, 2019 07:01 ET | Source: AC Immune SA

New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference

Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSPNew data further support 18F-PI-2620's potential as a new PET Tracer for...
March 27, 2019 07:00 ET | Source: AC Immune SA

New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference

Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as a new PET Tracer for...
March 21, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023Eli Lilly deal validates MorphomerTM platformInitiation of second Phase 2 trial of Tau antibody by partner...
March 21, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody by partner Genentech ...
March 04, 2019 10:28 ET | Source: AC Immune SA

AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress

Lausanne, Switzerland, March 4, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...